Stipple Bio will also be eligible for research, product development and commercialisation milestone payments, alongside tiered royalties on sales if Lilly successfully brings products from the collaboration to market.
Health
Eli Lilly expands cancer drug pipeline through US$5.9B Stipple Bio deal